Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
ABL001 - GME
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Efficacy of a combination of TKI and a novel allosteric inhibitor asciminib in chronic myeloid leukaemia | Faculty of Sciences, Engineering and Technology | University of Adelaide
ABL 001, Asciminib | New Drug Approvals
BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML | BLU Ampersand, Inc.
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
A, Selectivity profiles of GNF-2, GNF-5, and ABL-001 in contrast to two... | Download Scientific Diagram
ABL Bio
Asciminib, Supplier | ABL-001 | CAS 1492952-76-7 | ABL1 inhibitor | Sun-shinechem
Asciminib | C20H18ClF2N5O3 | CID 72165228 - PubChem
ABL001 strongly inhibited tumor progression of various human gastric... | Download Scientific Diagram
ABL-001 – A Branded Store
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
ABL 001, Asciminib | New Drug Approvals
ABL Bio
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
ABL-001-Amide-PEG3-acid | Fluorescent Probe | MedChemExpress
ABL-001 | 1492952-76-7
Novartis receives FDA Breakthrough Therapy designations for STAMP inhibitor asciminib (ABL001)
ABL Bio
ABL-001 | CAS# 1492952-76-7 | B1949 | BioVision, Inc.
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
ABL-001 XLR Male Connector, 2 A, Stainless Steel
